• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

检测肾盂和输尿管癌(包括发育异常)中的p53和bcl-2蛋白。

Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia.

作者信息

Furihata M, Sonobe H, Ohtsuki Y, Yamashita M, Morioka M, Yamamoto A, Terao N, Kuwahara M, Fujisaki N

机构信息

Department of Pathology II, Kochi Medical School, Nankoku, Japan.

出版信息

J Pathol. 1996 Feb;178(2):133-9. doi: 10.1002/(SICI)1096-9896(199602)178:2<133::AID-PATH455>3.0.CO;2-F.

DOI:10.1002/(SICI)1096-9896(199602)178:2<133::AID-PATH455>3.0.CO;2-F
PMID:8683378
Abstract

Ninety-four patients with transitional cell carcinoma (TCC) of the renal pelvis and ureter, including dysplastic lesions, were studied for p53 and bcl-2 protein expression by immunohistochemistry. Twenty-one patients were also studied for p53 gene mutations by direct sequencing and for bcl-2 gene rearrangement by Southern blot analysis. Overexpressed p53 protein was detected in 26 cases (27.7 per cent). bcl-2 immunostaining was observed in 21 tumours (22.3 per cent), including four cases with labelling for p53. Furthermore, the dysplastic lesions surrounding 19 p53-positive tumours also stained for p53. bcl-2 expression was also detected frequently in dysplastic lesions adjacent to 14 bcl-2-positive TCCs. Positive reactions of dysplastic lesions were also found adjacent to 37 bcl-2-negative tumours. p53 point mutation was detected in 6 of 21 cases. Five of the six cases were positive for p53 protein. blc-2 positivity was detected in 3 of 21 tumours, without bcl-2 gene rearrangements in the major breakpoint region. Overexpressed p53 protein was frequently detected in both high-grade (P < 0.05) and invasive tumours (P < 0.05). In three cases of p53-positive non-papillary invasive tumours, bcl-2 was found in non-invasive portions, but was not present in invasive areas. These findings suggest that overexpression (mutation) of p53 and/or bcl-2 protein may be early events in tumourigenesis and that p53 alterations in particular are essential for the maintenance of a malignant phenotype in tumour development.

摘要

对94例肾盂和输尿管移行细胞癌(TCC)患者(包括发育异常病变)进行免疫组织化学研究,检测p53和bcl-2蛋白表达。对21例患者还进行了直接测序检测p53基因突变以及Southern印迹分析检测bcl-2基因重排。26例(27.7%)检测到p53蛋白过表达。21例肿瘤(22.3%)观察到bcl-2免疫染色,其中4例同时有p53标记。此外,19例p53阳性肿瘤周围的发育异常病变也呈p53染色阳性。在14例bcl-2阳性TCC相邻的发育异常病变中也经常检测到bcl-2表达。在37例bcl-2阴性肿瘤相邻处也发现发育异常病变呈阳性反应。21例中有6例检测到p53点突变。6例中的5例p53蛋白呈阳性。21例肿瘤中有3例检测到bcl-2阳性,但主要断裂点区域未发现bcl-2基因重排。在高级别肿瘤(P<0.05)和浸润性肿瘤(P<0.05)中均经常检测到p53蛋白过表达。在3例p53阳性的非乳头状浸润性肿瘤中,bcl-2在非浸润部分存在,但浸润区域未出现。这些发现表明,p53和/或bcl-2蛋白的过表达(突变)可能是肿瘤发生的早期事件,尤其是p53改变对于肿瘤发展中恶性表型的维持至关重要。

相似文献

1
Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia.检测肾盂和输尿管癌(包括发育异常)中的p53和bcl-2蛋白。
J Pathol. 1996 Feb;178(2):133-9. doi: 10.1002/(SICI)1096-9896(199602)178:2<133::AID-PATH455>3.0.CO;2-F.
2
p53 overexpression and human papillomavirus infection in transitional cell carcinoma of the urinary bladder: correlation with histological parameters.膀胱移行细胞癌中p53过表达与人类乳头瘤病毒感染:与组织学参数的相关性
J Pathol. 1996 Jan;178(1):65-70. doi: 10.1002/(SICI)1096-9896(199601)178:1<65::AID-PATH451>3.0.CO;2-W.
3
Expression of Bcl-2 in lung neuroendocrine tumours: comparison with p53.Bcl-2在肺神经内分泌肿瘤中的表达:与p53的比较。
J Pathol. 1998 Mar;184(3):247-51. doi: 10.1002/(SICI)1096-9896(199803)184:3<247::AID-PATH994>3.0.CO;2-P.
4
Expression of bcl-2 oncoprotein in renal cell tumours.bcl-2癌蛋白在肾细胞肿瘤中的表达。
J Pathol. 1995 Nov;177(3):247-52. doi: 10.1002/path.1711770306.
5
p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.子宫内膜癌中p53过表达与bcl-2持续存在:浆液性乳头状和子宫内膜样亚型的比较
Gynecol Oncol. 1996 May;61(2):167-74. doi: 10.1006/gyno.1996.0120.
6
Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast.p53及其调控蛋白在乳腺叶状肿瘤中的表达改变
J Pathol. 1999 Oct;189(2):169-75. doi: 10.1002/(SICI)1096-9896(199910)189:2<169::AID-PATH408>3.0.CO;2-P.
7
Analysis of p53 and bcl-2 protein expression in the non-tumorigenic, pretumorigenic, and tumorigenic keratinocytic hyperproliferative lesions.非致瘤性、致瘤前性和致瘤性角质形成细胞过度增殖性病变中p53和bcl-2蛋白表达的分析。
J Cutan Pathol. 2004 Nov;31(10):643-51. doi: 10.1111/j.0303-6987.2004.00244.x.
8
p53 gene alterations and p53 protein in oral epithelial dysplasia and squamous cell carcinoma.口腔上皮发育异常和鳞状细胞癌中的p53基因改变及p53蛋白
J Pathol. 1996 Apr;178(4):415-21. doi: 10.1002/(SICI)1096-9896(199604)178:4<415::AID-PATH548>3.0.CO;2-1.
9
p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer.肺癌前体支气管病变中p53突变免疫表型及p53转录途径(Bcl2、Bax和Waf1)的失调
Clin Cancer Res. 1998 Jul;4(7):1609-18.
10
[The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival].[肾盂及输尿管移行细胞癌中p53和c-erb-2的表达及其与肿瘤进展和生存的关系]
Arch Esp Urol. 2002 Sep;55(7):792-6.

引用本文的文献

1
Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma.上尿路尿路上皮癌的预后基因特征
Curr Urol Rep. 2016 Feb;17(2):12. doi: 10.1007/s11934-015-0566-y.
2
Expression of p53 in upper urinary tract urothelial carcinoma.在上尿路尿路上皮癌中 p53 的表达。
Nat Rev Urol. 2011 Aug 2;8(9):516-22. doi: 10.1038/nrurol.2011.92.
3
Histopathological evaluation of apoptosis in cancer.癌症中细胞凋亡的组织病理学评估。
Am J Pathol. 1998 Oct;153(4):1041-53. doi: 10.1016/S0002-9440(10)65649-0.
4
Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer.Bcl-2蛋白表达:与结直肠癌中p53的关系及预后
Br J Cancer. 1998 Jun;77(11):1864-9. doi: 10.1038/bjc.1998.310.
5
Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter.细胞周期蛋白E和p53蛋白过表达在肾盂及输尿管癌中的预后意义
Br J Cancer. 1998 Mar;77(5):783-8. doi: 10.1038/bjc.1998.127.